

**REMARKS/ARGUMENTS**

Responsive to the Official Action of September 10, 2008 and the requirement for restriction presented in it, applicants elect the invention according to Group I, claims 1-8 drawn to compounds/compositions of formula (I), wherein the variables R1-R3 together with the nitrogen atom which they are linked to do not form a heterocycle system, and method of their use.

Responsive to the comments on page 6, first full paragraph of the Action, the compound of claim 4 (R-4-trimethylammonium-3-(tetradecylcarbamoyl)-aminobutyrate) is the elected species. This response is made without traverse.


In preparing this response claims 1-5 have been amended and cast in the more traditional method of treatment format directing claims to methods of treating tumors such as leukemia, carcinoma, lymphoma, sarcoma, breast, lung, head and neck, rectum and bladder cancers, particularly leukemia and hepatocarcinoma. The therapeutic treatment can be applied at various stages of tumor growth, proliferation and diffusion.

Please examine the elected claims on the merits taking into account the document cited in the International Search Report in the underlying PCT application and the Information Disclosure Statement filed concurrently herewith. See also the discussion of this document beginning on line 26, page 4 of the subject application.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Arthur R. Crawford  
Reg. No. 25,327

ARC:eaw  
901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100